Lifevantage (LFVN) Competitors $10.71 +0.03 (+0.28%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$10.72 +0.00 (+0.05%) As of 09/16/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LFVN vs. ANAB, ORKA, XNCR, SIGA, OPT, ARVN, OLMA, KOD, ATYR, and AQSTShould you be buying Lifevantage stock or one of its competitors? The main competitors of Lifevantage include AnaptysBio (ANAB), Oruka Therapeutics (ORKA), Xencor (XNCR), Siga Technologies (SIGA), Opthea (OPT), Arvinas (ARVN), Olema Pharmaceuticals (OLMA), Kodiak Sciences (KOD), aTyr Pharma (ATYR), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry. Lifevantage vs. Its Competitors AnaptysBio Oruka Therapeutics Xencor Siga Technologies Opthea Arvinas Olema Pharmaceuticals Kodiak Sciences aTyr Pharma Aquestive Therapeutics AnaptysBio (NASDAQ:ANAB) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends. Is ANAB or LFVN more profitable? Lifevantage has a net margin of 4.29% compared to AnaptysBio's net margin of -107.66%. Lifevantage's return on equity of 33.75% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-107.66% -366.98% -30.58% Lifevantage 4.29%33.75%15.26% Do analysts recommend ANAB or LFVN? AnaptysBio presently has a consensus price target of $46.13, indicating a potential upside of 137.76%. Lifevantage has a consensus price target of $30.50, indicating a potential upside of 184.78%. Given Lifevantage's stronger consensus rating and higher possible upside, analysts plainly believe Lifevantage is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80Lifevantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in ANAB or LFVN? 35.3% of Lifevantage shares are owned by institutional investors. 33.5% of AnaptysBio shares are owned by insiders. Comparatively, 20.7% of Lifevantage shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher valuation & earnings, ANAB or LFVN? Lifevantage has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$91.28M5.95-$145.23M-$4.48-4.33Lifevantage$228.53M0.59$9.81M$0.7414.47 Which has more risk & volatility, ANAB or LFVN? AnaptysBio has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500. Comparatively, Lifevantage has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Does the media prefer ANAB or LFVN? In the previous week, AnaptysBio had 3 more articles in the media than Lifevantage. MarketBeat recorded 8 mentions for AnaptysBio and 5 mentions for Lifevantage. AnaptysBio's average media sentiment score of 1.32 beat Lifevantage's score of 0.57 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lifevantage 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryLifevantage beats AnaptysBio on 11 of the 17 factors compared between the two stocks. Get Lifevantage News Delivered to You Automatically Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFVN vs. The Competition Export to ExcelMetricLifevantageMED/DENTAL IndustryMedical SectorNASDAQ ExchangeMarket Cap$135.54M$15.93B$5.73B$10.31BDividend Yield1.69%1.58%5.90%4.63%P/E Ratio14.4716.9075.8626.51Price / Sales0.592.30528.72123.58Price / Cash9.7213.0137.1760.46Price / Book3.893.3412.796.29Net Income$9.81M$472.94M$3.28B$270.51M7 Day Performance-4.63%-3.71%0.81%1.95%1 Month Performance-20.61%-7.49%4.60%6.33%1 Year Performance7.10%-3.90%70.39%25.62% Lifevantage Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFVNLifevantage4.0004 of 5 stars$10.71+0.3%$30.50+184.8%+7.9%$135.54M$228.53M14.47260ANABAnaptysBio2.4206 of 5 stars$22.19+1.3%$46.13+107.9%-49.9%$613.13M$91.28M-4.95100News CoveragePositive NewsAnalyst ForecastORKAOruka Therapeutics2.2632 of 5 stars$15.80-3.4%$40.38+155.5%-42.5%$612.32MN/A-5.62N/AXNCRXencor3.9614 of 5 stars$8.41-1.6%$22.25+164.6%-59.2%$609.81M$110.49M-3.50280Positive NewsSIGASiga Technologies1.427 of 5 stars$8.66+2.9%N/A+12.5%$602.92M$138.72M7.6640OPTOpthea0.4711 of 5 stars$3.41+7.2%$1.33-60.9%+2.4%$583.10M$30K0.008Positive NewsUpcoming EarningsGap UpHigh Trading VolumeARVNArvinas2.9215 of 5 stars$7.94+1.4%$19.76+148.9%-69.6%$574.86M$263.40M-7.86420Positive NewsOLMAOlema Pharmaceuticals2.8355 of 5 stars$7.58-8.8%$24.00+216.6%-35.4%$570.35MN/A-3.8370Gap UpKODKodiak Sciences3.8202 of 5 stars$9.79-6.9%$11.75+20.0%+248.1%$555.68MN/A-2.5890ATYRaTyr Pharma2.4979 of 5 stars$5.46-2.7%$23.25+325.8%-43.5%$549.71M$230K-6.8253Trending NewsAnalyst ForecastGap UpAQSTAquestive Therapeutics2.2664 of 5 stars$5.01-7.6%$10.29+105.3%-1.8%$540.50M$57.56M-7.16160 Related Companies and Tools Related Companies AnaptysBio Competitors Oruka Therapeutics Competitors Xencor Competitors Siga Technologies Competitors Opthea Competitors Arvinas Competitors Olema Pharmaceuticals Competitors Kodiak Sciences Competitors aTyr Pharma Competitors Aquestive Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LFVN) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifevantage Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifevantage With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LFVN Stock Alerts